164
Participants
Start Date
March 2, 2020
Primary Completion Date
February 1, 2022
Study Completion Date
February 1, 2022
Single target immunomodulation
Single target immunomodulation compromise of drugs which very specifically target cytokines, chemokines or specific receptors, which are involved in the pathofysiology of COVID-19. For instance, tociluzimab (IL-6 receptor blocker), Anakinra (IL-1 receptor blocker), Eculizimab (Complement inhibitor C5), etc.
Standard of care
Standard of care during COVID-19 pandemic including steroids.
Erasmus Medical Centre, Rotterdam
Lead Sponsor
Amsterdam UMC
OTHER
Leiden University Medical Center
OTHER
St. Antonius Hospital
OTHER
Erasmus Medical Center
OTHER